Quipt Home Medical Corp. (QIPT)
NASDAQ: QIPT · IEX Real-Time Price · USD
3.360
-0.070 (-2.04%)
May 31, 2024, 4:00 PM EDT - Market closed
Quipt Home Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Quipt Home Medical stock have an average target of 9.00, with a low estimate of 8.00 and a high estimate of 10. The average target predicts an increase of 167.86% from the current stock price of 3.36.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for QIPT stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +167.86% | May 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +138.10% | May 17, 2024 |
| Raymond James | Raymond James | Buy → Hold Downgrades $10 | Buy → Hold | Downgrades | $10 | +197.62% | Feb 16, 2024 |
| Benchmark | Benchmark | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +197.62% | Dec 20, 2023 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +227.38% | Jun 14, 2023 |
Financial Forecast
Revenue This Year
267.54M
from 221.74M
Increased by 20.65%
Revenue Next Year
289.05M
from 267.54M
Increased by 8.04%
EPS This Year
-0.03
from -0.07
EPS Next Year
0.11
from -0.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 284.9M | 306.7M | 409.9M | 520.1M | 598.2M |
| Avg | 267.5M | 289.1M | 341.0M | 505.3M | 581.1M |
| Low | 254.5M | 273.3M | 292.0M | 485.5M | 558.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 28.5% | 14.6% | 41.8% | 52.6% | 18.4% |
| Avg | 20.7% | 8.0% | 18.0% | 48.2% | 15.0% |
| Low | 14.8% | 2.2% | 1.0% | 42.4% | 10.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.07 | 0.25 | 0.97 | 1.27 | 1.64 |
| Avg | -0.03 | 0.11 | 0.38 | 1.24 | 1.60 |
| Low | -0.08 | 0.05 | 0.03 | 1.19 | 1.53 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 793.5% | 234.7% | 32.7% |
| Avg | - | - | 252.2% | 225.2% | 28.9% |
| Low | - | - | -72.8% | 212.4% | 23.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.